# Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

> **NCT05848128** · PHASE3 · COMPLETED · sponsor: **Mimetogen Pharmaceuticals USA, Inc.** · enrollment: 642 (actual)

## Conditions studied

- Dry Eye Syndromes
- Dry Eye Disease
- Kerato Conjunctivitis Sicca

## Interventions

- **DRUG:** 5% Tavilermide ophthalmic solution
- **OTHER:** Vehicle ophthalmic solution

## Key facts

- **NCT ID:** NCT05848128
- **Lead sponsor:** Mimetogen Pharmaceuticals USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-28
- **Primary completion:** 2024-05-11
- **Final completion:** 2024-05-11
- **Target enrollment:** 642 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05848128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05848128, "Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05848128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*